MarketCap
Facebook
X
Telegram
Amedisys Balance Sheet 2024-2006 | AMED
Brief balance sheet overview of Amedisys
The comparison uses five available annual reports from the 2020–2024 interval.
Over the period, assets gained +36.5%, moving from $1.6 billion to $2.1 billion. CAGR near 8.1% shows consistent growth.
Assets outpaced liabilities, +36.5% versus +26.7%. Dependence on external funding declined.
Internal capital represents 53% of the balance sheet, previously 51.7%. This is a strong capital position.
Net debt to equity stands at 0.05x; the current burden does not look excessive.
The cash share moved from 5.3% to 14.2%. A higher figure generally provides more room in an adverse scenario.
By the end of the period, accumulated earnings were $791.2 million; the change from the start was +84%.
Conclusion
The indicators point to a strong balance sheet position for Amedisys: funding is balanced and liability risks appear controlled.
Annual Balance Sheet Amedisys
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
62 M | 262 M | 399 M | 418 M | 150 M | 208 M | -12.8 M | 2.48 M | 62.8 M | 72.5 M | 108 M | 29.6 M | 88.2 M | 97.4 M | 61.6 M | 136 M | 283 M | - | - |
Long Term Debt |
339 M | 362 M | 419 M | 432 M | 204 M | 231 M | 5.78 M | 78.2 M | 87.8 M | 95 M | 104 M | 33 M | 66.9 M | - | 145 M | 171 M | 286 M | - | - |
Long Term Debt Current |
25.9 M | 26.3 M | 33.5 M | 31.2 M | 30 M | 27.8 M | 1.61 M | 10.6 M | - | - | - | - | - | 33.9 M | 37.2 M | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 294 M | 12 M | 82 M | 91.5 M | 99.5 M | 110 M | 41.5 M | 71.6 M | 116 M | - | - | - | - | - |
Total Current Liabilities |
514 M | 474 M | 356 M | 374 M | 456 M | 327 M | 222 M | 215 M | 181 M | 175 M | 162 M | 312 M | 205 M | 222 M | 216 M | 229 M | 205 M | - | - |
Total Liabilities |
959 M | 940 M | 870 M | 881 M | 756 M | 621 M | 234 M | 297 M | 273 M | 275 M | 272 M | 354 M | 276 M | 338 M | 420 M | 436 M | 508 M | - | - |
Retained Earnings |
791 M | 748 M | 758 M | 639 M | 430 M | 246 M | 120 M | 204 K | -30.5 M | -67.8 M | -64.8 M | -77.6 M | 18.6 M | 102 M | 485 M | 372 M | 236 M | - | - |
Total Assets |
2.14 B | 2.06 B | 1.98 B | 1.86 B | 1.57 B | 1.26 B | 717 M | 813 M | 734 M | 685 M | 670 M | 726 M | 731 M | 858 M | 1.3 B | 1.17 B | 1.07 B | - | - |
Cash and Cash Equivalents |
303 M | 126 M | 54.1 M | 45.8 M | 83.4 M | 30.3 M | 20.2 M | 86.4 M | 30.2 M | 27.5 M | 8.03 M | 17.3 M | 14.5 M | 48 M | 120 M | 34.5 M | 2.85 M | 56.2 M | 84.2 M |
Book Value |
1.18 B | 1.12 B | 1.11 B | 976 M | 811 M | 642 M | 483 M | 516 M | 461 M | 410 M | 398 M | 372 M | 454 M | 520 M | 880 M | 736 M | 562 M | - | - |
Total Shareholders Equity |
1.13 B | 1.07 B | 1.11 B | 976 M | 811 M | 640 M | 482 M | 515 M | 460 M | 410 M | 397 M | 372 M | 452 M | 519 M | 878 M | 735 M | 561 M | 448 M | 364 M |
All numbers in USD currency
Quarterly Balance Sheet Amedisys
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
326 M | 333 M | 339 M | 344 M | 351 M | 356 M | 362 M | 367 M | 370 M | 373 M | 419 M | 443 M | - | 430 M | 432 M | 435 M | 179 M | 231 M | 204 M | 204 M | 204 M | 204 M | 232 M | 232 M | 232 M | 232 M | 5.78 M | 5.8 M | 5.8 M | 5.8 M | 78.2 M | 78.2 M | 78.2 M | 78.2 M | 87.8 M | 87.8 M | 87.8 M | 87.8 M | 91.6 M | 91.6 M | 91.6 M | 91.6 M | 104 M | 104 M | 104 M | 104 M | 33 M | 33 M | 33 M | 33 M | 66.9 M | 66.9 M | 66.9 M | 66.9 M | 112 M | 112 M | 112 M | 112 M | 153 M | 162 M | 163 M | 179 M | 197 M |
Total Liabilities |
940 M | 940 M | 959 M | 939 M | 938 M | 947 M | 940 M | 934 M | 922 M | 814 M | 870 M | 913 M | - | 888 M | 881 M | 989 M | 724 M | 784 M | 756 M | 756 M | 756 M | 756 M | 621 M | 621 M | 621 M | 621 M | 234 M | 234 M | 234 M | 234 M | 297 M | 297 M | 297 M | 297 M | 273 M | 273 M | 273 M | 273 M | 271 M | 271 M | 271 M | 271 M | 272 M | 272 M | 272 M | 272 M | 354 M | 354 M | 354 M | 354 M | 276 M | 276 M | 276 M | 276 M | 338 M | 338 M | 338 M | 338 M | 416 M | 442 M | 438 M | 445 M | 441 M |
Retained Earnings |
880 M | 852 M | 791 M | 812 M | 795 M | 762 M | 748 M | 729 M | 703 M | 783 M | 758 M | 726 M | - | 671 M | 639 M | 605 M | 560 M | 480 M | 430 M | 430 M | 430 M | 430 M | 246 M | 246 M | 246 M | 246 M | 120 M | 120 M | 120 M | 120 M | 204 K | 204 K | 204 K | 204 K | -30.5 M | -30.5 M | -30.5 M | -30.5 M | -67.8 M | -67.8 M | -67.8 M | -67.8 M | -64.8 M | -64.8 M | -64.8 M | -64.8 M | -77.6 M | -77.6 M | -77.6 M | -77.6 M | 18.6 M | 18.6 M | 18.6 M | 18.6 M | 102 M | 102 M | 102 M | 102 M | 463 M | 441 M | 409 M | 334 M | 298 M |
Total Assets |
2.22 B | 2.18 B | 2.14 B | 2.14 B | 2.12 B | 2.09 B | 2.06 B | 2.03 B | 1.98 B | 1.95 B | 1.98 B | 1.98 B | - | 1.91 B | 1.86 B | 1.94 B | 1.6 B | 1.57 B | 1.57 B | 1.57 B | 1.57 B | 1.57 B | 1.26 B | 1.26 B | 1.26 B | 1.26 B | 717 M | 717 M | 717 M | 717 M | 813 M | 813 M | 813 M | 813 M | 734 M | 734 M | 734 M | 734 M | 682 M | 682 M | 682 M | 682 M | 670 M | 670 M | 670 M | 670 M | 726 M | 726 M | 726 M | 726 M | 731 M | 731 M | 731 M | 731 M | 858 M | 858 M | 858 M | 858 M | 1.26 B | 1.27 B | 1.22 B | 1.13 B | 1.08 B |
Cash and Cash Equivalents |
337 M | 285 M | 303 M | 245 M | 157 M | 121 M | 126 M | 94 M | 111 M | 69.1 M | 40.5 M | 31.5 M | 48.8 M | 70.9 M | 42.7 M | 128 M | 91.6 M | 77.3 M | 81.8 M | 81.8 M | 81.8 M | 81.8 M | 30.3 M | 30.3 M | 30.3 M | 30.3 M | 20.2 M | 20.2 M | 20.2 M | 20.2 M | 86.4 M | 86.4 M | 86.4 M | 86.4 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 8.03 M | 8.03 M | 8.03 M | 8.03 M | 17.3 M | 17.3 M | 17.3 M | 17.3 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 48 M | 48 M | 48 M | 48 M | 128 M | 116 M | 82 M | 45.2 M | 898 K |
Book Value |
1.27 B | 1.25 B | 1.18 B | 1.2 B | 1.18 B | 1.14 B | 1.12 B | 1.09 B | 1.06 B | 1.13 B | 1.11 B | 1.07 B | - | 1.02 B | 976 M | 949 M | 876 M | 790 M | 811 M | 811 M | 811 M | 811 M | 642 M | 642 M | 642 M | 642 M | 483 M | 483 M | 483 M | 483 M | 516 M | 516 M | 516 M | 516 M | 461 M | 461 M | 461 M | 461 M | 410 M | 410 M | 410 M | 410 M | 398 M | 398 M | 398 M | 398 M | 372 M | 372 M | 372 M | 372 M | 454 M | 454 M | 454 M | 454 M | 520 M | 520 M | 520 M | 520 M | 848 M | 828 M | 784 M | 686 M | 643 M |
Total Shareholders Equity |
1.23 B | 1.2 B | 1.13 B | 1.15 B | 1.18 B | 1.14 B | 1.07 B | 1.09 B | 1.06 B | 1.13 B | 1.05 B | 1.07 B | 1.04 B | 1.02 B | 931 M | 949 M | 874 M | 788 M | 809 M | 809 M | 809 M | 809 M | 640 M | 640 M | 640 M | 640 M | 482 M | 482 M | 482 M | 482 M | 515 M | 515 M | 515 M | 515 M | 460 M | 460 M | 460 M | 460 M | 410 M | 410 M | 410 M | 410 M | 397 M | 397 M | 397 M | 397 M | 372 M | 372 M | 372 M | 372 M | 452 M | 452 M | 452 M | 452 M | 519 M | 519 M | 519 M | 519 M | 847 M | 826 M | 783 M | 685 M | 642 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Amedisys, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
China
USA
Russia
Germany
Britain
